News

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth

Endeavour Vision leads investment in Intelycare’s artificial intelligence-driven nurse staffing platform, to support the next phase of the company’s growth Geneva, February 20, 2020 - Endeavour Vision led the Series B funding round for Boston-based IntelyCare, along with Kaiser Permanente Ventures and Generator Ventures, allowing the company to [...]

2020-02-20T18:22:04+00:00February 20th, 2020|All News, Company News|

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage

IntelyCare Completes Largest Venture Round in Nursing; Raises $45M to Solve Nationwide Workforce Shortage Endeavour Vision, Kaiser Permanente Ventures, and Generator Ventures Join Existing Investors in Round, Leveraging Gig Economics to Close Projected 1 Million Nurse Shortfall by 2030; Builds on Company’s Exceptional Momentum QUINCY, MA – February [...]

2020-02-20T14:06:24+00:00February 20th, 2020|All News, Company News|

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma

Molecular Partners Receives Orphan Drug Designation for MP0250 for Multiple Myeloma Zurich-Schlieren, Switzerland, December 27, 2019. Molecular Partners AG (SIX:MOLN), a clinical stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, announces the receipt of Orphan Drug Designation by the US Food and Drug [...]

2020-01-06T14:14:02+00:00January 6th, 2020|All News, Company News|

Interview with Bradley Paddock, CEO of CeQur

Interview with Bradley Paddock, CEO of CeQur In June 2019, Bradley Paddock joined CeQur®, as Chief Executive Officer. We spoke to Bradley to hear about his first 6 months in the company and discuss the up-coming U.S. launch of its three-day insulin delivery device for type 2 diabetes.  [...]

2020-01-06T11:51:06+00:00January 6th, 2020|All News, Blog|

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress 2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. - November 11, 2019 - Gynesonics, a women’s healthcare company focused on the development [...]

2019-11-29T16:01:15+00:00November 12th, 2019|All News, Company News|

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar [...]

2019-10-22T11:02:49+01:00October 14th, 2019|All News, Company News, Previous Sectors|

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension

V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension CAESAREA, Israel, September 12, 2019 – V-Wave Ltd., [...]

2019-10-10T10:05:26+01:00September 13th, 2019|All News, Company News|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy [...]

2019-10-10T10:53:56+01:00September 9th, 2019|All News, Company News, Previous Sectors|